ATTN: Medical Health Officers and Branch Offices
Public Health Nursing Administrators and Assistant Administrators
Holders of Communicable Disease Control Manuals

Re: Update to Communicable Disease Control Manual, Chapter 1: Meningococcal Disease and Chapter 2: Immunization, Part 2 – Immunization of Special Populations and Part 4 – Biological Products

Chapter 1: Meningococcal Disease

- ‘Communicable Diseases and Immunization Service, BCCDC’ has replaced the previous service line name of ‘Immunization Programs and Vaccine Preventable Diseases Service, BCCDC’.
- The after-hours phone number for the immediate reporting of cases and contacts has been revised with the new after-hours number.

Please remove page numbers: 4, 5 & 13 dated June and September 2017
Please add new page numbers: 4, 5 & 13 dated October 2018

Chapter 2: Immunization

Part 2 - Immunization of Special Populations

Specific Immunocompromising Conditions

Human Immunodeficiency Virus (HIV) Infection

- The table “Recommended vaccines for those with HIV infection” has been revised to indicate that infants who are exposed to or infected with HIV should be immunized with rotavirus vaccine according to the routine schedule. Subsequent content related to rotavirus vaccine in this subsection has been updated accordingly.
- Oral cholera vaccine has been removed from the list of live vaccines as an inactivated preparation is used in Canada.

Please remove page numbers: 1 & 2 dated January 2017
Please add new page numbers: 1 & 2 dated October 2018
Other High Risk Conditions

Women Who are Pregnant or Planning a Pregnancy

- Footnote B related to Tdap vaccine has been updated as per the most recent NACI recommendation.

Please remove page numbers: 1 & 2 dated May 2016
Please add new page numbers: 1 & 2 dated October 2018

Part 4 – Biological Products

Pneumococcal Vaccines

Pneumococcal Polysaccharide Vaccine (Pneumovax® 23)

- Solid organ or islet cell transplant (candidate or recipient) has been added to the list of those for whom a once-only revaccination should be offered 5 years after the initial immunization.

Please remove page numbers: 1 & 2 dated October 2017
Please add new page numbers: 1 & 2 dated October 2018

Rabies Vaccines

Rabies Vaccine for POST-EXPOSURE Prophylaxis (IMOVAX® Rabies and RabAvert®)

- SEROLOGICAL TESTING AND RE-VACCINATION has been revised to remove the recommendation for post-series serological testing for those on chloroquine.

Please remove page numbers: 1-3 dated May 2017
Please add new page numbers: 1-3 dated October 2018

Rotavirus Vaccines

Rotarix®

- CONTRAINDICATIONS: Footnote E has been added to indicate that infants exposed to or infected with HIV should be immunized with rotavirus vaccine according to the routine schedule.

Please remove page numbers: 1-3 dated April 2018
Please add new page numbers: 1-3 dated October 2018
RotaTeq®

- CONTRAINDICATIONS: Footnote E has been added to indicate that infants exposed to or infected with HIV should be immunized with rotavirus vaccine according to the routine schedule.

Please remove page numbers: 1-3 dated April 2018
Please add new page numbers: 1-3 dated October 2018

Zoster Vaccines

Shingrix®

- The new product page for recombinant zoster vaccine (SHINGRIX®) has been added.

Please add new page numbers: 1 & 2 dated October 2018

Zostavax® II

- The section “Recommended by the National Advisory Committee on Immunization but not Provided Free in BC” has been revised to indicate that Zostavax® II may be considered when recombinant zoster vaccine (Shingrix®) is contraindicated or unavailable.
- CONTRAINDICATIONS has been revised to include that pregnancy should be avoided for 3 months following live zoster immunization.
- PRECAUTIONS has been revised to include that live zoster vaccine should be used with precaution in those who are breastfeeding.
- CONTRAINDICATIONS, Footnote B, has been updated to indicate that live zoster vaccine can be considered for those receiving topical, inhaled or low-dose immunosuppressive therapy.

Please remove page numbers: 1 & 2 dated March 2017
Please add new page numbers: 1 & 2 dated October 2018

Please also remove the Table of Contents for Part 4 – Biological Products dated August 27, 2018 and replace with the enclosed updated Table of Contents dated October 2018.
If you have any questions or concerns, please contact Christine Halpert, Senior Practice Leader, BCCDC (telephone: 604-707-2555 / email: christine.halpert@bccdc.ca) or Stephanie Meier, Public Health Resource Nurse, BCCDC (telephone: 604-707-2577 / email: stephanie.meier@bccdc.ca).

Sincerely,

Monika Naus MD MHSc FRCPC FACPM
Medical Director
Communicable Diseases & Immunization Service
BC Centre for Disease Control

pc:
Provincial Health Officer
Dr. Bonnie Henry
Dr. Mark Tyndall
Executive Medical Director
BC Centre for Disease Control, and
Deputy Provincial Health Officer

BC Ministry of Health, Population & Public Health Division:
Craig Thompson
Director, Immunization
Wendy Trotter
Executive Director,
Public Health Services